Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D09GEK
|
|||
| Former ID |
DNCL002360
|
|||
| Drug Name |
ASP3026
|
|||
| Synonyms |
ASP3026; 1097917-15-1; ASP-3026; ASP 3026; N2-[2-Methoxy-4-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]phenyl]-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-1,3,5-triazine-2,4-diamine; UNII-HP4L6MXF10; HP4L6MXF10; 2-N-[2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl]-4-N-(2-propan-2-ylsulfonylphenyl)-1,3,5-triazine-2,4-diamine; MGGBYMDAPCCKCT-UHFFFAOYSA-N; MLS006011176; GTPL7740; SCHEMBL2827739; CHEMBL3545360; C29H40N8O3S; QCR-144; EX-A140; DTXSID90149038; AOB6601; MolPort-028-720-342; BCP06436; 2229AH; ZINC68120928; s8054
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Diffuse large B-cell lymphoma [ICD-11: 2A81] | Phase 1 | [1], [2] | |
| Company |
Astellas Pharma
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C29H40N8O3S
|
|||
| Canonical SMILES |
CC(C)S(=O)(=O)C1=CC=CC=C1NC2=NC(=NC=N2)NC3=C(C=C(C=C3)N4CCC(CC4)N5CCN(CC5)C)OC
|
|||
| InChI |
1S/C29H40N8O3S/c1-21(2)41(38,39)27-8-6-5-7-25(27)33-29-31-20-30-28(34-29)32-24-10-9-23(19-26(24)40-4)36-13-11-22(12-14-36)37-17-15-35(3)16-18-37/h5-10,19-22H,11-18H2,1-4H3,(H2,30,31,32,33,34)
|
|||
| InChIKey |
MGGBYMDAPCCKCT-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 1097917-15-1
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | ALK tyrosine kinase receptor (ALK) | Target Info | Modulator | [1] |
| KEGG Pathway | Non-small cell lung cancer | |||
| WikiPathways | Differentiation Pathway | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7740). | |||
| REF 2 | ClinicalTrials.gov (NCT01401504) Study of an Investigational Drug, ASP3026, in Patients With Solid Tumors. U.S. National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.